Finding out you are pregnant can turn an ordinary Tuesday into a full-blown medication detective story. Suddenly, every bottle in the medicine cabinet starts looking suspicious, especially prescription drugs used to control autoimmune disease. If you take Xeljanz, also known as tofacitinib, you may be wondering whether you can continue it during pregnancy or while breastfeeding.

The practical answer is not quite as simple as a yes-or-no sticker on a pill bottle. Xeljanz is generally not recommended during pregnancy unless a specialist decides the benefit clearly outweighs the potential risk. It is also not recommended while breastfeeding under the current product labeling. However, an accidental early pregnancy exposure does not automatically mean something bad will happen, and it does not mean anyone should panic, blame themselves, or abruptly make treatment decisions alone.

The goal is to balance two very real issues: the possible effects of medication exposure and the risks of uncontrolled inflammatory disease. That is why pregnancy planning with rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, or ankylosing spondylitis is less like flipping a switch and more like coordinating a small orchestra. Everyone needs the same sheet music.

The Quick Answer: Is Xeljanz Safe During Pregnancy or Breastfeeding?

During pregnancy: Xeljanz is usually avoided because there is not enough high-quality human pregnancy data to confirm that it is safe. Animal studies found fetal harm at higher exposures, including pregnancy loss and developmental abnormalities. Human reports have not shown a clear increase in birth defects so far, but the number of documented pregnancies is still too limited to rule out risk confidently.

During breastfeeding: The manufacturer advises against breastfeeding while taking Xeljanz. For immediate-release Xeljanz tablets or oral solution, breastfeeding should not resume until at least 18 hours after the final dose. For extended-release Xeljanz XR, the waiting period is at least 36 hours after the final dose.

Important distinction: “Not enough evidence to call it safe” is different from “known to cause harm in every pregnancy.” Medicine is rarely a dramatic courtroom scene with a single gavel slam. In this case, the evidence is incomplete, which is exactly why clinicians usually prefer medications with stronger pregnancy and breastfeeding data whenever possible.

What Is Xeljanz, and Why Does Pregnancy Change the Conversation?

Xeljanz is the brand name for tofacitinib, a prescription medication in the Janus kinase, or JAK inhibitor, class. It works by changing immune-system signaling that contributes to inflammation. It may be prescribed for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and certain juvenile arthritis conditions.

For many people, Xeljanz can make a major difference in daily life. It may reduce painful swelling, help control urgent bowel symptoms, improve mobility, and make it easier to function without feeling like every joint has joined a protest march. That benefit matters.

Pregnancy changes the decision because the developing fetus is exposed to the parent’s biology, disease activity, nutrition, inflammation, infections, and potentially certain medications. Small-molecule drugs such as tofacitinib may cross biological barriers differently from larger biologic medications. Researchers therefore look closely at animal studies, pregnancy registries, accidental exposures, medication databases, and long-term infant outcomes.

Unfortunately, pregnant people are often excluded from clinical trials for understandable ethical reasons. The result is a frustrating paradox: clinicians want strong pregnancy safety data, but those data are difficult to gather before a medication reaches real-world use.

Can You Take Xeljanz While Pregnant?

Why Xeljanz Is Usually Avoided During Pregnancy

Current prescribing information says that available human pregnancy data are insufficient to establish whether Xeljanz raises the risk of major birth defects, miscarriage, or other poor maternal or fetal outcomes. That sentence may sound bureaucratic, but its meaning is straightforward: there simply are not enough reliable human data to label the medication as pregnancy-safe.

Animal reproductive studies provide another reason for caution. At exposure levels above those typically used in people, tofacitinib was associated with fetal loss and developmental abnormalities in rats and rabbits. Animal findings do not always predict what will happen in humans, but they are important warning signals, particularly when human evidence is limited.

For this reason, clinicians often try to transition patients to a treatment with more established pregnancy safety information before conception. The best alternative depends on the condition being treated, how severe it is, prior medication response, infection history, blood-clot risk, and whether the person is planning to breastfeed after delivery.

What Human Pregnancy Data Actually Show

The available human information is limited but somewhat reassuring in one narrow sense: published reports of early pregnancy exposure have not identified a clear pattern of birth defects or miscarriage that proves Xeljanz is harmful in humans. Some pregnancy safety database reports have included healthy live births, miscarriages, elective terminations, and pregnancies with incomplete follow-up.

However, small numbers cannot answer every question. A few dozen or even a few hundred reported pregnancies may be enough to raise useful clues, but not enough to confidently exclude uncommon complications. Researchers still need more information about dose, timing of exposure, disease severity, other medications, pregnancy complications, infant development, and breastfeeding exposure.

That uncertainty is why a clinician may say, “We do not have evidence that it definitely causes a problem, but we also do not have enough evidence to say it is safe.” It is not a satisfying sentence, but it is an honest one.

Uncontrolled Disease Can Also Affect Pregnancy

A common mistake is to think the medication is the only risk in the room. In reality, active inflammatory disease can also create problems during pregnancy. Poorly controlled rheumatoid arthritis or ulcerative colitis may be associated with higher chances of complications such as preterm delivery, low birth weight, and babies who are small for gestational age.

That does not mean Xeljanz should automatically be continued. It means treatment should not be stopped without a backup plan. A flare during pregnancy can affect sleep, nutrition, mobility, pain levels, blood counts, stress, and overall health. For someone with ulcerative colitis, a severe flare may involve dehydration, rectal bleeding, weight loss, or hospitalization. For someone with inflammatory arthritis, a major flare can make ordinary movement feel like trying to fold laundry during an earthquake.

The safest pregnancy plan is often the one that keeps the underlying disease controlled with the medication strategy best supported for that specific diagnosis and stage of pregnancy.

What to Do If You Become Pregnant While Taking Xeljanz

If you get a positive pregnancy test while taking Xeljanz, contact your prescribing clinician and obstetric provider as soon as possible. Avoid making snap decisions based on a late-night internet search, a social media comment, or an aunt’s friend’s neighbor who “read something once.”

Your healthcare team may review:

• The date of your last menstrual period and estimated gestational age.
• The Xeljanz dose and whether you take immediate-release tablets or Xeljanz XR.
• How long you have been taking the medication.
• Your underlying condition and current disease activity.
• Other medications, supplements, and medical conditions.
• Whether a pregnancy-compatible treatment option is appropriate.
• Whether pregnancy registry enrollment may be available.

Depending on the situation, your clinicians may recommend stopping Xeljanz, transitioning to another treatment, monitoring disease activity closely, or involving a maternal-fetal medicine specialist. The right response varies from one patient to another. A person with mild, stable disease may need a very different plan than someone with severe ulcerative colitis that has previously required hospitalization.

Should You Stop Xeljanz Before Trying to Conceive?

Many specialists recommend discussing a medication transition before attempting pregnancy rather than waiting for a positive pregnancy test. Planning ahead creates time to choose an alternative treatment, confirm disease stability, update vaccinations when appropriate, review supplements, and make sure the replacement therapy is working before pregnancy begins.

The manufacturer advises people of reproductive potential to consider pregnancy planning and prevention while using Xeljanz. However, there is no universal “one-size-fits-all” washout plan that every patient should follow without medical guidance. The appropriate timing may depend on your disease, current dose, other medications, and the medication selected as a replacement.

In other words, do not treat a medication switch like changing coffee brands. A good preconception plan ideally happens before you are already counting weeks and googling “is this normal?” at 2:13 a.m.

Can You Breastfeed While Taking Xeljanz?

The Current Recommendation

Under current Xeljanz prescribing information, breastfeeding is not recommended during treatment. The product labeling advises waiting at least 18 hours after the last dose of immediate-release Xeljanz tablets or oral solution before breastfeeding again. For Xeljanz XR, the extended-release version, the recommended waiting period is at least 36 hours after the final dose.

These intervals are based on the medication’s elimination pattern and are intended to allow the drug level in the body to decline substantially after treatment stops. They are not a suggestion to take Xeljanz every day and simply time breastfeeding around a dose without medical guidance.

Why the Breastfeeding Evidence Is Complicated

Small reports have measured low levels of tofacitinib in breast milk. A few breastfed infants described in published reports did not have obvious short-term adverse effects. That is encouraging, but it is not enough to declare the medication harmless for every nursing infant.

Researchers still do not have large, long-term studies that can reliably answer questions about infant immune function, infection risk, vaccine response, growth, or development. The uncertainty matters even more for newborns, premature babies, or infants with medical conditions, because their immune systems and drug-handling abilities are still developing.

Think of the current evidence as a small flashlight, not stadium lighting. It lets clinicians see a little, but not enough to map every corner of the room.

Can You “Pump and Dump” After Taking Xeljanz?

“Pump and dump” is often misunderstood. Pumping and discarding milk does not make medication leave your bloodstream faster. It may help maintain milk supply or relieve breast fullness during a planned interruption, but it does not erase drug exposure from the body.

If a clinician recommends pausing breastfeeding because of Xeljanz, they may discuss pumping to preserve supply while waiting for the recommended interval after the final dose. This should be planned with the prescribing clinician, pediatrician, and, when possible, a lactation consultant. Feeding plans may include stored breast milk, donor milk where available, or infant formula, depending on the family’s circumstances and the baby’s needs.

Are There Safer Alternatives to Xeljanz During Pregnancy or Breastfeeding?

Possibly, but the correct alternative depends entirely on the condition being treated. Some medications have more pregnancy and lactation experience than tofacitinib, including certain conventional disease-modifying drugs and some biologic therapies. For example, some people with inflammatory arthritis may be candidates for medications such as hydroxychloroquine, sulfasalazine, azathioprine, or specific TNF inhibitors. People with ulcerative colitis may have a different set of options, including therapies aimed at maintaining bowel remission before and during pregnancy.

That does not mean every alternative works for every diagnosis. A medication that is useful for rheumatoid arthritis may not be the right choice for ulcerative colitis, and a medication that worked beautifully before pregnancy may not be appropriate during breastfeeding. It is also possible that a treatment considered acceptable in pregnancy may not be ideal for a particular person because of prior side effects, infections, liver disease, clotting history, or lack of response.

The right question is not, “What medication is safest in general?” It is, “What medication can safely control my disease during this stage of life?”

Questions to Ask Your Doctor About Xeljanz, Pregnancy, and Breastfeeding

Bring a short written list to your appointment. Pregnancy brain is real, postpartum brain is real, and remembering complicated medication questions while holding a crying baby is an advanced sport.

• Should I stop Xeljanz now, or should I transition to another medication first?
• How active is my underlying condition right now?
• What pregnancy-compatible treatment options fit my diagnosis?
• How long should I wait after stopping Xeljanz before trying to conceive?
• What should I do if my symptoms flare after changing medication?
• Can I breastfeed with my replacement treatment?
• Should I work with maternal-fetal medicine, rheumatology, gastroenterology, or dermatology during pregnancy?
• Is pregnancy registry enrollment available for my exposure?

When to Seek Urgent Medical Care

Pregnancy and postpartum symptoms should never be brushed off simply because you have an autoimmune condition or take immune-modifying medication. Seek urgent medical care for severe shortness of breath, chest pain, coughing up blood, one-sided leg swelling or pain, severe abdominal pain, heavy vaginal bleeding, high fever, fainting, signs of severe dehydration, or symptoms that feel dramatically different from your usual disease flare.

Xeljanz has important safety considerations beyond pregnancy, including serious infections and blood-clot risks in certain patients. Pregnancy itself also changes clotting risk. That does not mean every ache is an emergency, but it does mean unusual symptoms deserve prompt medical attention rather than a heroic attempt to “wait it out.”

Real-World Experiences: What Pregnancy and Breastfeeding Cases Can Teach Us

Real-world experiences with Xeljanz during pregnancy and breastfeeding are valuable, but they must be interpreted carefully. They are not the same as large randomized trials, and they cannot predict exactly what will happen in any one pregnancy. Still, the stories and case reports that have been documented offer useful lessons about how these decisions unfold outside a textbook.

One common pattern involves an unplanned pregnancy. A person may be taking Xeljanz successfully for ulcerative colitis or inflammatory arthritis, feel well for the first time in years, and then discover a positive pregnancy test before any medication changes have been made. The first reaction is often fear: fear about the medication, fear about stopping it, and fear that a disease flare will return at the worst possible time. In these situations, clinicians usually focus first on gathering accurate details rather than making assumptions. Timing, dose, disease history, and other medications all matter.

Published pregnancy safety reports have included healthy births after early Xeljanz exposure. That can be reassuring for someone who took the medication before realizing they were pregnant. At the same time, those reports also include miscarriages and pregnancies with incomplete follow-up. Because miscarriage is unfortunately common in the general population and autoimmune disease can independently affect pregnancy, it is often impossible to know whether a particular outcome was related to the medication, the disease, other health factors, or chance.

Another real-world lesson is that medication transitions work best when they happen before conception whenever possible. Patients who plan ahead can often trial a replacement therapy, monitor their symptoms, and enter pregnancy with stable disease. That stability matters. A medication may be less familiar during pregnancy, but a severe inflammatory flare is not a harmless alternative. Good preconception care is not about achieving perfection; it is about reducing avoidable surprises.

Breastfeeding decisions can be especially emotional. Some parents feel strongly about breastfeeding and may experience grief, disappointment, or guilt if they are advised to pause or avoid nursing while receiving Xeljanz. Those feelings are understandable. Feeding a baby is not a morality contest, and formula, donor milk, stored milk, combination feeding, or breastfeeding after a medically planned medication change can all be loving, healthy choices.

The limited breastfeeding reports available so far are cautiously encouraging because measured milk levels have generally been low and no major short-term infant problems were reported in the small number of described cases. But the keyword is small. A few reassuring reports cannot replace the larger, longer studies needed to assess immune effects, infections, growth, development, and vaccine response. That is why the product label and many experts remain conservative.

Families also learn that teamwork makes a huge difference. The most helpful care plans often involve the prescribing specialist, obstetric clinician, pediatrician, pharmacist, and sometimes a maternal-fetal medicine specialist or lactation consultant. Each professional sees a different part of the puzzle. The rheumatologist may focus on joint inflammation, the gastroenterologist on bowel disease control, the obstetric team on fetal development, and the pediatrician on infant feeding and health.

Perhaps the most important takeaway from real-world experience is this: early exposure is a reason to call your healthcare team, not a reason to spiral. Planned pregnancy is ideal, but life is not always ideal. Accurate information, timely follow-up, disease control, and compassionate support are far more useful than panic.

Bottom Line

Can you take Xeljanz while pregnant or breastfeeding? In most cases, clinicians try to avoid Xeljanz during pregnancy and recommend not breastfeeding while taking it because human safety data remain limited and animal studies raise concern. The current labeling advises waiting at least 18 hours after the last immediate-release dose, or 36 hours after the last Xeljanz XR dose, before resuming breastfeeding.

Still, an accidental exposure does not automatically predict a poor outcome. Human reports have not identified a clear pattern of increased birth defects from early exposure, but the available evidence is too limited to prove safety. The best next step is not to make a medication decision alone. Contact your prescribing clinician and pregnancy care team promptly so they can help protect both your health and your baby’s health with a plan tailored to your condition.

SEO Tags